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1. Introduction 
Late-onset Alzheimer's disease (LOAD) is the most common cause of dementia and the fifth 
leading cause of death in Americans older than 65 years.1 Although other major causes of 
death have decreased, deaths due to LOAD have been rising dramatically over the past two 
decades, between 2000 and 2006 they increased by 46.1%.1 Clinically, LOAD is characterized 
by progressive cognitive decline in particular in the memory domain. Neuropathologically it 
is characterized by the aggregation and deposition of misfolded proteins, in particular 
aggregated ǃ-amyloid (Aǃ) peptide in the form of extracellular senile (or neuritic) 
“plaques,” and hyperphosphorlylated tau (τ) protein in the form of intracellular 
neurofibrillary “tangles” (NFTs). These changes are often accompanied by microvascular 
damage, vascular amyloid deposits, inflammation, microgliosis, and loss of neurons and 
synapses. 
Although twin studies suggest that  37% to 78% of the variance in the age-at-onset of LOAD 
can be attributed to additive genetic effects,2 few genes have been identified and validated, 
and these genes likely explain less than 50% of the genetic contribution to LOAD. This is the 
upper bound of explained heritability in other complex diseases for which—unlike LOAD—
significant association has been demonstrated for several common loci of large effect (i.e., 
ORs > 2 to > 3), such as age-related macular degeneration. Thus, a substantial proportion of 
the heritability for LOAD remains unexplained by the currently known susceptibility genes. 
A likely explanation for the difficulty in gene identification is that LOAD is a multifactorial 
complex disorder with both genetic and environmental components, and that multiple 
genes with small effects are likely to contribute. 
Several neuroimaging measures correlate with LOAD risk and progression, in particular the 
volumes of the hippocampus, parahippocampus and entorhinal cortex, and the cerebral 
grey matter. Also these measures appear to have a substantial genetic contribution reflected 
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by heritability estimates ranging from 40% to 80%.3-5 Advances in brain imaging and high 
throughput genotyping enable new approaches to study the influence of genetic variation 
on brain structure and function. As a result, imaging genetics has become an emergent 
transdisciplinary research field, where genetic variation is evaluated using imaging 
measures as quantitative traits (QTs) or continuous phenotypes. Imaging genetics studies 
have advantages over traditional case-control designs. An important consideration is that 
QT association studies have increased statistical power and thus decreased sample size 
requirements. Additionally, imaging phenotypes may be closer to the underlying biological 
etiology of AD, making it easier to identify underlying genes. Together with studies of the 
genetics of brain structure and function among normal individuals which have been 
extended to the entire human lifespan from childhood through extreme old age,6-8 the data 
of such studies provide an invaluable backdrop for understanding the genetic influences on 
neuroanatomy and neurophysiology and are powerful tools for understanding the genetics 
of neurodegenerative diseases associated with changes in these brain structures such as 
LOAD. In this chapter, we summarize the current evidence relating genetic variation with 
LOAD and review the usefulness of imaging endophenotypes in identification of genes 
increasing susceptibility to LOAD. 
2. Imaging endophenotypes in LOAD 
Structural MRI. On structural magnetic resonance imaging (LOAD) is characterized by 
atrophy of the medial temporal lobe, foremostly the hippocampus and the amygdala (Figure 
1),9 which may further involve the posterior cortex,1 occipital lobes, precuneus and posterior 
cingulate.10 Atrophy in the hippocampus and entorhinal cortex is associated with a decline 
in memory function, progression of memory impairment and an increased risk of LOAD.11 
However, these structural changes on MRI are not specific to LOAD and not sufficient to 
establish a definitive diagnosis of LOAD, as similar atrophy is observed in other 
neurodegenerative disorders and normal aging. In addition, while nonspecific white matter 
changes appear frequently in healthy elderly individuals, such changes are also common in 
elderly people with cognitive decline, stroke or MCI. Nevertheless, several studies have 
suggested that certain structural MRI biomarkers possess some degree of discriminative 
diagnostic power. For example, evidence exists that in LOAD, the corpus callosum 
(particularly the anterior area) exhibits atrophy. This change helps to distinguish LOAD 
from frontotemporal dementia, in which the posterior area of the corpus callosum shows 
greater atrophy than the anterior area of this brain structure.12 There is also evidence that 
among patients with amnestic MCI, those who convert to LOAD show greater atrophy in 
the hippocampus and the inferior and middle temporal gyri than those who do not convert 
to LOAD.13 
Functional MRI. Functional MRI (fMRI) can visualize neuronal activity either during rest or 
in association with a task that activates specific brain regions. The most common method is 
blood oxygen level-dependent (BOLD) fMRI, which measures alterations in blood flow on 
the basis of changes in deoxyhemoglobin. As the deoxyhemoglobin concentration depends 
on neuronal activity, BOLD reflects brain activity. This technique is widely used in research 
and in the diagnosis of various brain disorders because of its high sensitivity and easy 
implementation. 
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Fig. 1. LOAD Endophenotypes on MRI 
BOLD signals depend on several anatomical, physiological and imaging parameters, and 
can be interpreted qualitatively or semiquantitatively. As a result, interindividual and 
intraindividual variability limits the use of such signals in the differential diagnosis of 
dementia- causing disorders. Nevertheless, fMRI can facilitate the characterization of 
functional abnormalities in specific diseases. People with LOAD exhibit reduced brain 
activity in parietal and hippocampal regions in comparison with healthy controls when 
undergoing memory encoding tasks.14-16 In addition, some studies have found different 
neuronal activity patterns in healthy controls and patients with MCI. Recent advances in 
fMRI have allowed intrinsic functional networks in the human brain to be defined. The 
study of cognitive–behavioral function in the early stages of neurodegenerative disorders 
may allow the identification of the neuroanatomical networks affected by these diseases, 
and may assist in the differential diagnosis of the various disorders that underlie dementia. 
PET and single-photon emission CT. PET and single-photon emission CT (SPECT) have 
been widely explored as diagnostic tools for dementia, and both techniques have shown 
good diagnostic and prognostic capabilities. PET studies have mostly used the tracer 
2-[18F]-fluoro-2-deoxy-d-glucose (18F-FDG), which provides a measure of cerebral glucose 
metabolism and, hence, indirectly demonstrates synaptic activity. In the early stages of 
LOAD, 18F-FDG-PET reveals a characteristic pattern of symmetric hypometabolism in the 
posterior cingulate and parietotemporal regions that spreads to the prefrontal cortices 
(Figure 2a). These changes are distinct from the changes in cerebral glucose metabolism that 
are seen in healthy controls and cases of other forms of dementia, and the extent of 
hypometabolism inversely correlates with the degree of cognitive impairment.17 18F-FDG-
PET has a high sensitivity (94%) but a low specificity (73–78%) for the diagnosis of 
dementia.18 SPECT, which involves studying regional blood flow with Tc-
hexamethylpropyleneamine oxime, has a similar specificity to 18F-FDG-PET for this 
condition.19 A number of low-molecular-weight tracers have been developed for PET to 
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assess Aǃ deposits in vivo. The most frequently used tracer is Pittsburgh compound B (PIB). 
Compared with healthy controls, patients with LOAD show increased 11C-PIB retention in 
cortical regions targeted by Aǃ deposits (Figure 2b).20 Deposition of this peptide seems to 
reach a plateau by the early stages of LOAD. In MCI, PIB binding is bimodal, with ≈ 50% of 
patients showing an increase in 11C-PIB binding, resembling the 11C-PIB retention that is 
seen in LOAD, while the other ≈ 50% of patients exhibit low levels of 11C-PIB binding that 
are similar to the levels seen in controls.21 In MRI studies, 11C-PIB binding correlated 
positively with atrophy in the amygdala and hippocampus but not other cortical areas, 
suggesting that various brain areas have different susceptibilities to Aǃ deposit-mediated 
toxicity, or that amyloid deposition is nonessential for neurodegeneration.21 New PET 
tracers for amyloid deposits, such as 18F-FDDNP, are being developed. In studies 
comparing 11C-PIB and 18F-FDDNP, these tracers showed differences in regional binding 
and in the cognitive domains with which they seem to be associated, suggesting that these 
tracers measure related but different characteristics of LOAD.22 
 
 
Fig. 2. A) FDG PET patterns characteristic of metabolic activity in cognitively normal 
individuals and patients with LOAD. Red: high FDG uptake, Blue: low FDG uptake. 
Compared to persons aging normally, persons with LOAD show decreased bilateral glucose 
metabolism particularly in the temporal and parietal regions. B) PIB PET images 
characteristic of elderly individuals without cognitive impairment and patients with LOAD.  
Red: high PiB retention, Purple: low PiB retention. The image of the LOAD case shows red 
and yellow areas indicating high concentrations of PiB in the brain thereby suggesting high 
amounts of amyloid deposits. 
3. Genetic influences on brain morphological endophenotypes 
Elucidating the extent to which genetic and environmental factors influence normal brain 
structure is of great importance for understanding age-related normal and pathological 
changes in brain and cognition. Twin studies, which estimate heritability based on data from 
monozygotic (MZ) and dizygotic (DZ) twin pairs, provide the optimal genetic method for 
clarifying this issue because they allow decomposing the variance of any variable into genetic, 
shared environmental influences, and unique individual-specific environmental influences.  
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As MZ twin pairs are genetically identical (with rare exceptions due to somatic mutations) 
while DZ twin pairs share on average 50% of their segregating genes, variation of a certain 
measure is considered heritable if MZ twin pairs resemble each other for this measure more 
closely than DZ twin pairs. An influence of shared environmental factors is suspected when 
correlations in DZ twin pairs are >50% of the MZ twin pair correlation.23 Unique 
environmental factors determine the extent to which MZ twins do not resemble each other. 
Extended twin-studies include additional relatives thereby increasing the statistical power 
to detect the influences of environmental influences shared by members from the same 
family.  
Heritability of Brain Volumes and Structures. To date, more than 30 twin studies on brain 
imaging measures have been performed that aim to define the genetic contribution to brain 
structures (reviewed by Krasuski et al. and Karas et al9, 10). Overall, these studies 
demonstrated substantial heritability of these endophenotypes, particularly for larger 
structures.  
Twin studies using magnetic resonance imaging (MRI), found high heritability estimates of 
global brain measures including intracranial volume (>72%),3, 9, 11, 24-26 total brain volume 
(66–97%),3, 11, 24, 27-30 lobar tissue (in particular the temporal and parietal cortices),25, 30, 31 total 
gray matter volume3, 11, 24 and total white matter volume.3, 11, 24 Brain areas that in contrast 
seem to be under stronger environmental control include the gyral patterning of the 
cortex,27, 32 the volume of the lateral ventricles,12, 24, 26, 29, 33 and the volume of the 
hippocampus.11, 12, 24, 29, 34, 35  It is important to point out that some of these studies did not 
correct for total cranial volume or height when measuring brain volumes. Although it is 
likely that the ratio of brain volume/total cranial volume is comparable among monozygotic 
twins, it remains possible that this lack of correction has led in some studies to spurious 
results.  
More recent studies have predominantly examined possible genetic effects on specific brain 
areas using voxel-based morphometry36 and cortical thickness measures. Overall, these 
studies confirmed in particular the high heritabilities for the frontal, parietal and temporal 
cortices. In a study by Thompson et al., that constructed detailed three-dimensional maps 
based on a genetic continuum of similarity in grey matter in groups of unrelated subjects as 
well as DZ and MZ twins, genetic factors influenced in particular anatomical regions that 
include frontal and language-related cortices (ie., sensorimotor, middle frontal, anterior 
temporal and Wernicke’s cortices; r2(MZ) > 0.8, p < 0.05).5 In a study by Holshoff Pol et al.37 
which examined both gray and white matter density in a large sample of 54 monozygotic 
and 58 dizygotic twin pairs and 34 of their siblings, genetic factors significantly influenced 
white matter density of the superior occipitofrontal fascicle, corpus callosum, optic 
radiation, and corticospinal tract, as well as grey matter density of the medial frontal, 
superior frontal, superior temporal, occipital, postcentral, posterior cingulate, and 
parahippocampal cortices (heritability>0.69).37 In a study by Wright et al., voxel-based 
morphometry revealed moderate heritabilities (42-66%) for temporal/parietal neocortical 
areas and paralimbic structures.29 In a study by Rijsdijk et al.,38 heritability estimates were 
only significant for left posterior cingulate and right dorsal anterior cingulate gray matter 
concentrations (46% and 37%, respectively). In a  recent study that derived both surface-
based and voxel-based representations of brain structure,39 both  heritability estimates for 
thickness and surface area were highest for the temporal and parietal lobes. In addition, this 
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study suggested that grey matter volume is more closely related to surface area than cortical 
thickness suggesting that surface area and cortical thickness measurements should be 
considered separately and preferred over gray matter volumes for imaging genetic studies. 
Only one study has measured the heritability estimates for changes in brain volumes over 
time.  In this study which used structural MRI, the genetic contributions to variability in 
intracranial volume, corpus callosum, and lateral ventricles in healthy elderly were high (88-
92%)26 but did not change after 4 years follow-up.40 
4. Genetic epidemiology of LOAD 
Genetically, AD is categorized into two forms: (1) familial cases with Mendelian inheritance 
of predominantly early-onset (<60 years, early-onset familial AD [EOFAD]), and (2) 
“sporadic” cases with less apparent or no familial aggregation and later age of onset (≥60 
years, late-onset AD [LOAD]). It is important to note that this traditional dichotomization is 
overly simplistic as there are cases of early-onset AD without evidence for Mendelian 
transmission while, conversely, LOAD is frequently observed with a strong familial 
clustering, sometimes resembling a Mendelian pattern.  
In contrast to early-onset Alzheimer’s disease which is caused by autosomal dominant 
mutations in the APP (amyloid precursor protein), PSEN1 (presenilin 1) and PSEN2 
(presenilin 2) genes, the genetics of LOAD is more complex. The genes involved in LOAD 
increase disease risk and are not inherited in a Mendelian fashion. First-degree relatives of 
patients with LOAD have twice the expected lifetime risk of this disease of people who do 
not have a LOAD-affected first-degree relative.41 In addition, LOAD occurs more frequently 
in monozygotic than in dizygotic co-twins,42 suggesting a substantial genetic contribution 
to this disorder. In the largest twin study of dementia, involving 11,884 participants in the 
Swedish registry who were aged >65 years, 395 twin pairs were identified in which either 
one or both twins had LOAD.42 This study demonstrated a heritability of 58–79% for 
LOAD, depending on the model that was used in the data analysis. 
Apolipoprotein E. APOE is the only established susceptibility gene for LOAD and maps to 
chromosome 19 in a cluster with the genes encoding translocase of outer mitochondrial 
membrane 40 (TOMM40), apolipoprotein C1 and apolipoprotein C2. APOE is a lipid-
binding protein that is expressed in humans as one of three common isoforms, which are 
encoded by three different alleles, namely APOE ε2, APOE ε3 and APOE ε4. The presence of 
a single APOE ε4 allele is associated with a 2–3-fold increase in the risk of LOAD, while the 
presence of two copies of this allele is associated with a fivefold increase in the risk of this 
disease. 
Each inherited APOE ε4 allele lowers the age of LOAD onset by 6–7 years. Furthermore, the 
presence of this allele is associated with memory impairment, MCI, and progression from 
MCI to dementia.38 APOE ε4 has been suggested to account for as much as 20–30% of LOAD 
risk. 
Despite the studies linking APOE ε4 with LOAD, the presence of this allele is neither 
necessary nor sufficient for disease: among participants in the Framingham study,39 55% of 
those who were homozygous for APOEε4, 27% of those with one copy of this allele and 9% 
of those without an APOE ε4 allele developed LOAD by 85 years of age. Segregation 
analyses conducted in families of patients with LOAD support the presence of at least four 
to six additional major LOAD risk genes.43 Additional genetic risk variants. After APOE, 
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the best-validated gene LOAD risk is the sortilin-related receptor 1 (SORL1) gene, which is 
located on chromosome 11q23. SorL1 belongs to a group of five type I transmembrane 
receptors (the others being sortilin, SorCS1, SorCS2 and SorCS3) that are highly expressed in 
the CNS and are characterized by a luminal, extracellular vacuolar protein sorting 10 
domain. From family-based and population-based studies that, together, included over 
6,000 individuals from four ethnic groups, Rogaeva et al. identified two haplotypes in the 3’ 
and 5’ regions of SORL1 that are associated with LOAD risk.44 In addition, these researchers 
demonstrated that SorL1 promotes the translocation and retention of APP in subcellular 
compartments that exhibit low secretase activity, thereby reducing the extent of proteolytic 
breakdown into both amyloidogenic and nonamyloidogenic products.44 As a consequence, 
underexpression of SORL1 leads to overexpression of Aǃ and an increased risk of LOAD. 
Several subsequent studies replicated these initial genetic association findings, and the 
results were further validated by a collaborative, unbiased metaanalysis of all published 
genetic data sets that included a total of 12,464 LOAD cases and 17,929 controls.45 In the 
past year, several studies demonstrated that, in addition, genetic variation in the SORL1 
homolog SORCS1 influences LOAD risk, cognitive performance, APP processing and Aǃ1–
40 and Aǃ1–42 levels through an effect on Ǆ-secretase processing of APP,46, 47 further 
emphazising the role of sortilin-related proteins in LOAD etiology. 
Genome-wide association studies48-50 for LOAD using large numbers of cases and controls 
have revealed modest effect sizes for several genes on LOAD risk, with odds ratios in the 
range of 1.1–1.5, although most of these studies have only confirmed the association of 
APOE with this disease. One such study showed that variants of TOMM40—which is 
proximally located to and in linkage disequilibrium with APOE—were associated with 
LOAD risk, but whether these genetic associations are independent of the APOE locus 
remains unclear. 
Together, two genome-wide association studies identified variants in the clusterin gene 
(CLU),16, 51 the phosphatidylinositol- binding clathrin assembly protein gene (PICALM)16 
and complement receptor type 1 gene (CR1)51 as being associated with LOAD and several 
subsequent studies replicated these findings, but functional data confirming the roles in 
LOAD of the proteins encoded by these genes are still lacking. Clusterin is a lipoprotein that 
is expressed in mammalian tissues and is incorporated into amyloid plaques. This protein 
binds to soluble Aǃ in CSF, forming complexes that can penetrate the BBB. Clusterin levels 
are positively correlated with the number of APOE ε4 alleles, suggesting a compensatory 
induction of CLU in the brains of LOAD patients with the APOE ε4 allele, who show low 
brain levels of APOE. CR1 encodes a protein that is likely to contribute to Aǃ clearance from 
the brain, while PICALM protein is involved in clathrin-mediated endocytosis, allowing 
intracellular trafficking of proteins and lipids such as nutrients, growth factors and 
neurotransmitters. PICALM protein also has a role in the trafficking of vesicle-associated 
membrane protein 2, a soluble N-ethylmaleimide-sensitive factor attachment protein 
receptor that is involved in the fusion of synaptic vesicles to the presynaptic membrane in 
neurotransmitter release. A third large genome-wide association study confirmed the 
associations of PICALM and CLU with LOAD and reported two additional loci as being 
associated with LOAD52: rs744373, which is near the bridging integrator 1 gene (BIN1) on 
chromosome 2q14.3, and rs597668, which is located on chromosome 19q13.3. BIN1 is a 
member of the BAR (BIN–amphiphysin–Rvs) adaptor family, which has been implicated in 
caspase-independent apoptosis and membrane dynamics, including vesicle fusion and 
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trafficking, neuronal membrane organization, and clathrin-mediated synaptic vesicle 
formation. Of note, the latter process is disrupted by Aǃ. Changes in BIN1 expression have 
also been shown in aging mice and in transgenic mouse models of LOAD. The locus 
rs597668 is not in linkage disequilibrium with APOE, suggesting that the effect of this locus 
on LOAD risk is independent. Six genes are found in this region, of which at least two 
(genes encoding biogenesis of lysosomal organelles complex 1 subunit 3 and microtubule 
associated protein–microtubule affinity-regulating kinase 4) are implicated in molecular 
pathways linked to LOAD or other brain disorders. 
It is important to note, that the results of the published genome-wide association studies are 
informative, but that the genetic associations need functional validation. Indeed, such 
studies alone cannot prove causality or assess the biological significance of an observed 
genetic association. Genomewide association studies represent a method of screening the 
genome, but are limited in their ability to detect true associations. 
5. Genetic variation and neuroimaging measures in LOAD 
As described above, multiple neuroimaging measures that correlate with LOAD risk and 
progression appear to have genetic underpinnings, with heritability estimates ranging from 
40% to 80%. Recent studies that aimed to determine whether the discovered genetic risk 
factors for LOAD also influence these neuroimaging traits suggest that several of these 
candidate genes also influence specific LOAD imaging endophenotypes. Most studies chose 
hippocampal volume as the quantitative phenotype because of its sensitivity to the changes 
of early LOAD, and by far the best studied gene is APOE. In line with the strong and 
consistent results for APOE when using LOAD as the phenotype, most T-1 weighted MRI 
studies reported an association of APOE e4 with accelerated LOAD-related volume loss in 
the hippocampal region.53-56 This is supported by several studies exploring the effect of the 
APOE e4 allele on glucose metabolism using FDG-PET,57-60 or amyloid deposition using 
([¹¹C] PiB-PET. 61-63 
Few studies have examined the association between other genes and LOAD imaging 
measures, and most of these were GWAS studies. In a GWAS of 381 participants of the 
Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort, 21 chromosomal areas were 
associated with hippocampal atrophy.64 These candidate regions included the APOE, 
EFNA5, CAND1, MAGI2, ARSB, and PRUNE2 genes, which are involved in the 
regulation of protein degradation, apoptosis, neuronal loss and neurodevelopment. In the 
same study, APOE and TOMM40 were confirmed when LOAD was used as the 
phenotype of interest.64 Additional studies by the same group, that included a larger set 
of imaging phenotypes and used T1-weighted MRI, 65 voxel-based 
morphometry/FreeSurfer methods 66or 3D mapping of temporal lobe volume differences 
using tensor-based morphometry,67 confirmed  SNPs in APOE and TOMM40 as strongly 
associated with multiple brain regions (including hippocampal volume, entorhinal cortex 
volume, amygdala volume, cortical thickness measures, grey-matter density) and 
revealed other SNPs in or close to candidate genes that have been repeatedly associated 
with LOAD as described above (PICALM, SORL1, SORCS1, APP, CR1, BIN1). In addition 
these studies reported novel SNPs in proximity to the EPHA4, TP63, NXPH1, GRIN2B, 
NEDD9, DAPK1, IL1B, MYH13, TNK1, ACE, PRNP, PCK1 and GAPDHS genes.  Several 
www.intechopen.com
 
Genetic Risk Factors of Imaging Measures Associated with Late-Onset Alzheimer’s Disease 
 
301 
of these genes are biologically plausible. NXPH1 codes for neurexophilin-1, a protein 
implicated in synaptogenesis, that forms a tight complex with alpha neurexins, a group of 
proteins that promote adhesion between dendrites and axons. This adhesion is a key 
factor in synaptic integrity, the loss of which is a hallmark of AD. GRIN2B encodes the N-
methyl-D-aspartate glutamate receptor NR2B subunit, which is a target for memantine 
therapy to decrease excitotoxic damage. ACE has been shown to cleave amyloid beta in 
vitro and is in addition involved in blood pressure regulation. Both high and low blood 
pressure have been associated with LOAD.  
There have been few studies exploring the effects of specific candidate genes (other than 
APOE) on brain imaging phenotypes. Ho et al.68 investigated the relationship between an 
obesity-associated candidate gene (FTO) and regional brain volume differences in 206 ADNI 
control participants. Systematic brain volume deficits were detected in cognitively normal 
obesity-associated risk allele carriers, as well as in subjects with increased body mass index 
indicating that this obesity susceptibility gene is associated with detectable deficits in brain 
structure, which may indirectly influence future risk for neurodegenerative disease. In 129 
hypertensive individuals from a family-based cohort sampled from a Dutch genetically 
isolated population,69 four SNPs located at the 3'-end of SORL1 (rs1699102, rs3824968, 
rs2282649, rs1010159) were associated with frequency of microbleeds  which is potentially 
related to amyloid angiopathy. In the MIRAGE Study70 several SORL1 SNPs that have been 
reported to be associated with LOAD, were associated with hippocampal atrophy, 
cerebrovascular disease, and white matter hyperintensities. In a candidate gene study that 
used (FDG-PET) measurements as a quantitative pre-symptomatic endophenotype  in 158 
cognitively normal late-middle-aged APOEε4 homozygotes, heterozygotes, and non-
carriers,71 the GAB2 protective haplotype was associated with higher regional-to-whole 
brain FDG uptake in APOEε4 carriers. 
6. Discussion 
The work reviewed above indicates that there are various brain imaging measures that are 
useful endophenotypes associated with genetic liability for LOAD. The strongest evidence 
of heritability, linkage and/or association in studies of normal brain aging have been found 
for the medial frontal cortex, Heschl’s gyrus and postcentral gyrus, Broca’s area, anterior 
cingulate, gray matter of the parahippocampal gyrus and white matter of the superior 
occipitofrontal fasciculus. The high heritability for these endophenotypes seems to be 
present throughout life and seems to be functionally relevant. In contrast, the heritability of 
volume of the hippocampus, which is central to the formation of new memories and 
memory consolidation, the process for converting short-term memory into stored or long-
term memory,72  seems to be modest.  Support for an environmental component of 
hippocampus volume comes from a twin study of Ammon’s horn sclerosis73 in which only 
the twin of MZ pairs who had experienced prolonged, childhood febrile seizures developed 
sclerosis. This discordance in hippocampal response to trauma suggests susceptibility of this 
structure to environmental events. Mammalian studies reporting neurogenesis of the 
hippocampal dentate gyrus in adult animals even into senescence74, 75 suggest that the 
relatively stable size of the hippocampus throughout adulthood76, 77 may reflect a lifelong 
relative maintenance of volume 78, 79 through mechanisms such as neurogenesis and 
synaptogenesis with rich environmental stimulation75 even when genetically 
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compromised.80, 81 This speculation must, however, be tempered by the relatively small 
number of new neurons generated in confined regions of the hippocampus82 and the lack of 
evidence that volume necessarily reflects cell number. In any case, if neurogenesis could be 
adequately and functionally amplified, it may carry new promise for conditions affecting 
the hippocampus such as LOAD.  
The GWAS and candidate gene studies, however, which explored the impact of genetic 
variation on imaging endophenotypes of LOAD, do support an impact of genetic factors. In 
particular studies exploring the effect of APOE genotype on morphological changes 
consistently suggest a modulation of volume/structure dependent on level of genetic risk. 
Thus, taken together these studies of the genetics of brain structure and function among 
normal individuals suggest that variation in brain structure and function can be expected 
and that pathological states represent the extremes of this variation. They further indicate 
that the morphological characteristics of several brain structures represent both differential 
vulnerability to environmental influences and phenotypical expressions of different sets of 
genes, which may operate on morphology at different times throughout development and 
aging. As a consequence, these data provide a valuable background for understanding the 
genetics of neurodegenerative diseases associated with changes in brain structures including 
LOAD. They suggest that using these quantitative imaging traits may provide an 
informative phenotype and may increase statistical power.    
Although encouraging, this also raises some additional questions and challenges. First, are 
the genes mediating each endophenotype involved in abnormal brain aging and cognition at 
least partially distinct from each other? This is a key assumption of the endophenotype 
approach, yet empirical proof of this remains to be determined. A substantial degree of 
overlap appears likely for a number of the known genes associated with early- and late-
onset AD, at least including the APP, PSEN1, PSEN2, APOE, SORL1 and SORCS1, given 
that these genes are involved in either the production or processing of the ǃ-amyloid 
peptide. Nevertheless, each gene has a unique role in this cascade and it thus seems likely 
these loci will differ in their magnitudes of influence across the brain systems affected in this 
disorder. How do these genes (along with others that remain to be identified) coalesce in 
influencing liability to overt expression of LOAD? Are their effects additive or interactive? 
The answers to these questions depend on large-scale studies of genetically at-risk samples 
with and without environmental exposures and the use of sophisticated statistical modeling 
algorithms that can powerfully probe the resulting datasets for evidence of gene-gene and 
gene-environment interactions. Finally, are these endophenotypes and associated genes 
unique to cognitive impairment in LOAD, or are they shared by other diseases such as 
Dementia with Lewy Bodies, Parkinson’s disease or depression? Lewy body inclusions and 
Lewy neurites, the key pathological hallmarks of dementia with Lewy Bodies and 
Parkinson’s disease, are a frequent coexistent pathologic change observed in autopsy-
confirmed LOAD.   
The questions posed above raise considerable challenges for investigators attempting to 
unravel the genetic complexity of LOAD. Nevertheless, we have entered a new era in which 
conjoint advances in molecular genetics and dissection of the dementing phenotype are 
enabling rapid progress with multiple gene discoveries. These discoveries validate the 
dissection of this disorder into its more discretely determined subcomponents in order to 
elucidate the mechanisms underlying cognitive impairment in the elderly.  
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Author Subjects Age in years, mean (range) Brain region Heritability  
in % (95% CI) 
Reveley et 
al.33 (1984) 
18 MZ, 18 DZ NA LV 82-85% (NA) 
Bartley et 
al.27 (1997) 
10 MZ, 9 DZ MZ: 31 (19-54), DZ: 33 (18-29) TB 94% (NA) 
Carmelli et 
al.25 (1998) 
74 MZ, 71 DZ 68-79 years IC 91% (NA) 
Pennington 
et al.28 
(2000) 
Reading 
disability: 25 
MZ, 23 DZ; 
Non-Reading 
disability: 9 MZ, 
9 DZ 
Reading disability: MZ: 17.1, 
DZ: 16.8; Non-reading 
disability: MZ: 19.4, DZ: 18.7
TB 
Neocortex 
97% (NA) 
56% (NA) 
Pfefferbau
m et al.26 
(2000) 
45 MZ, 40 DZ MZ: 72.2, DZ: 71.4, range: 68-
78 
Subcortex 
IC 
CC 
LV 
70% (NA) 
81% (72-90) 
79% (69-89) 
79% (55-100) 
Posthuma 
et al.3 (2000) 
See Baaré et al 
(2001) 
See Baaré et al (2001) CB 88% (81-92) 
Sullivan et 
al.34 (2001) 
45 MZ, 40 DZ MZ: 72.2, DZ: 71.4, range: 68-
78 
HIP 40% (NA) 
Thompson 
et al.5 (2001) 
10 MZ, 10 DZ 48.2 ±3.4 Middle frontal 
sensimotor and 
anterior 
temporal 
cortices, Broca`s 
and Wernicke`s 
region (cortical 
thickness) 
90-95% (NA) 
Baaré et 
al.24 (2001) 
54 MZ, 58 DZ, 
34 sibs 
15 MZ, 18 DZ 
MZM: 31.2, MZF: 34.1, DZM: 
30.3, DZF: 30.6, OS: 30.3, sibs: 
29.0; range: 19-69 
75.7 ± years 
IC 
TB 
GM 
WM 
LV 
Size CC 
Microstructure 
CC (DTI) 
88% (82-92) 
90% (85-93) 
82% (73-88) 
87% (80-91) 
C: 59%  
(47-69), E: 41% 
(31-53) 
5:1 (NA) 
3:1 (NA) 
Geschwind 
et al.30 
(2002) 
72 MZ, 67 DZ MZ: 72.3, DZ: 71.8 Cerebral 
hemispheres 
65% (NA) 
Eckert  
et al.32 
(2002) 
27 MZ, 12 DZ MZ: 6.9-16.4, DZ: 6.1-15.0 Planum 
temporale 
asymmetry 
NA (NA) 
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Author Subjects Age in years, mean (range) Brain region Heritability  
in % (95% CI) 
Wright et 
al.29 (2002) 
10 MZ, 10 DZ MZ: 31 (19-54), DZ: 23 (18-29) TB 
LV 
CB 
Ventrolateral 
FR, cingulate, 
anterior/superi
or/transverse 
temp, 
retrosplenium 
66% (17-100) 
C: 48% (0-97), 
E: 50% (32-84) 
63%, E: 22% 
(NA) 
58-73% (NA) 
White et 
al.83 (2002) 
12 MZ, 12 
control pairs 
MZ: 24.5±7.2, controls: 
 24.4 ±7.2 
TB, GM, WM, 
CB 
CAU, PUT, 
THAL, cortical 
depth 
r>0.90 
r>0.75 
Scamvouge
ras et al.84 
(2003) 
14 MZ, 12 DZ MZ: 16-41, DZ: 18-32 CC 94% (NA) 
Pfefferbau
m et al.40 
(2004) 
34 MZ, 37 DZ 4-year longitudinal follow-
up 
T1: 68-80 years, T2: 72-84 
years 
CC (T1) 
CC (T2) 
LV (T1) 
LV (T2) 
89% (NA) 
92% (NA) 
92% (NA) 
88% (NA) 
Wallace et 
al.31 (2006) 
90 MZ, 37 DZ MZ: 11.9, DZ: 10.9, range: 5-
19 
TB 
GM 
WM 
FR, TEMP, 
PAR 
CB 
LV 
89% (67-92) 
82% (50-87) 
85% (56-90) 
77-88% (50-90) 
49% (13-83) 
31% (0-67), C: 
24% (0-58), E: 
45% (33-60) 
Hulshoff 
Pol et al.37 
(2006) 
See Baaré et al 
(2001) 
See Baaré et al (2001) WM (SOF, CC, 
CST) 
GM, MFL, SFL, 
STL, CING, 
PARAHIP, 
AMYG, OCC 
69-82% (NA) 
55-85% (NA) 
AMYG, amygdala; CAU, caudate; CB, cerebellum; CC, corpus callosum; CI, confidence interval; CING, 
cingulate; CST, corticospinal tract; DTI, diffusion tensor imaging; DZ, dizygotic; DZF, dizygotic female; 
DZM, dizygotic male; FR, frontal lobe; GM, gray matter; HIP, hippocampus; IC, intracranial volume; 
LH, left handed; LV, lateral ventricles; MFL, medial frontal lobe; MZ, monozygotic; MZF, monozygotic 
female; MZM, monozygotic male; NA, not available; OCC, occipital lobe; occ-front-temp, occipito-
fronto temporal; PAR, parietal lobe; PARAHIP, parahippocampal gyrus; PUT, putamen; SOF, superior 
orbitofrontal; TB, total brain; TEMP, temporal lobe; THAL, thalamus; SFL, superior frontal lobe; STL, 
superior temporal lobe; WM, white matter. 
Table 1. Studies on heritability of human brain volumes 
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It is important to note that - despite their utility in the context of etiological research on 
LOAD - endophenotypes have not proven to have great utility in the clinical distinction of 
dementing disorders. As described above, the different forms of dementia show substantial 
clinical and pathological overlap, and likely do not reflect completely separate underlying 
pathologies or genetic causes but rather a continuous spectrum of disease. Therefore, 
although they more realistically reflect variation in the underlying causes of illness, the use 
of endophenotypic assessments in diagnostic or treatment contexts is difficult. 
In conclusion, given that the pathways from genotypes to end-stage phenotypes are 
circuitous at best, discernment of endophenotypes more proximal to the effects of genetic 
variation can improve statistical power and thereby be a powerful tool in the identification 
of genes linked to complex disorders. They can help understand how environmental and 
genetic factors interact to influence disease susceptibility and expression, and can help 
identify targets for the development of new treatment and prevention strategies. 
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